Research across Cancer
Related studies from across the Cancer family.
Single-port robot-assisted partial nephrectomy reduces estimated blood loss by 16.62 mL compared to multi-port
Single Port Surgery Shows Less Blood Loss for Renal Tumors
This meta-analysis of 442 patients with low-complexity renal tumors found that single-port robot-assisted partial nephrectomy (SP-RAPN) resu…
A single-port robotic approach may reduce blood loss during certain kidney tumor surgeries compared to multi-port methods.
Adjunctive hemostatic agents in partial nephrectomy show no transfusion benefit
Adding topical agents to kidney surgery does not reduce blood loss
This meta-analysis of 3408 patients undergoing partial nephrectomy for T1 renal tumors found no significant difference in blood transfusion …
New data shows that adding certain clotting agents during kidney surgery does not lower the need for blood transfusions or prevent complicat…
Comparative Analysis of Robot Assisted and Laparoscopic Partial Nephrectomy for Renal Tumors
Robot-assisted surgery shows fewer complications for certain kidney tumors
A meta-analysis of 6,202 patients suggests robot-assisted partial nephrectomy offers comparable oncologic outcomes with superior renal prese…
A large review suggests robot-assisted surgery may lead to less blood loss and better kidney function for patients with specific renal tumor…
Robot-assisted radical nephrectomy reduces conversion rates and blood loss compared to laparoscopic surgery for complex tumors
Robot-assisted Surgery Shows Benefits for Complex Renal Tumors
This meta-analysis of 4,163 patients evaluated robot-assisted radical nephrectomy (RARN) versus laparoscopic radical nephrectomy (LRN) for h…
Robotic surgery may reduce blood loss and the need for transfusions while preserving kidney function in patients with complex renal tumors.
Kidney-directed SBRT shows modest renal function decline in inoperable patients
Small study shows kidney function drops after radiation for hard-to-treat tumors
This prospective phase 2 single-arm trial evaluated kidney-directed SBRT in 30 patients with primary or metastatic renal tumors who were med…
Radiation to treat kidney tumors may lower kidney function over two years, even when surgery is not an option.
Nephrometry Scores Show Limited Discrimination for Adverse Outcomes After RAPN in Larger Renal Tumors
Tumor complexity scores predict longer surgery time but not major complications in kidney cancer removal
This retrospective cohort study of 109 patients with pT1b–pT2a renal tumors found that PADUA and RENAL nephrometry scores had limited discri…
Scores measuring kidney tumor complexity predicted longer surgery time but failed to predict major complications in 109 patients.
Radical nephrectomy performed for renal inflammatory myofibroblastic tumor in an elderly female
Rare Kidney Tumor Treated Successfully With Surgery Alone
This is a case report of an elderly female patient who underwent radical right nephrectomy for a renal inflammatory myofibroblastic tumor.
A rare kidney tumor was removed with surgery, and no recurrence was seen at 6 months. But this is just one case.
Hong Kong consensus statement updates management for locally advanced and metastatic renal cell carcinoma
New Kidney Cancer Rules Change How Doctors Treat Metastasis
This guideline presents a consensus statement developed by 6 urologists and 8 clinical oncologists in Hong Kong regarding locally advanced a…
New expert rules update kidney cancer care with more drug options and clearer surgery plans.
Savolitinib and durvalumab combination yields response rates of 34% to 53% in papillary renal cancer patients
New Hope for a Tough Kidney Cancer Type
This single-arm phase II study evaluated savolitinib and durvalumab in 41 treatment-naïve or pretreated patients with papillary renal cancer…
A new drug pair breaks the shield blocking treatment for a rare kidney cancer type, offering patients a chance at longer survival after stan…
Simlukafusp alfa plus atezolizumab with or without bevacizumab shows antitumor activity in metastatic renal cell carcinoma
Does adding bevacizumab nearly triple the time before kidney cancer grows back?
A phase Ib randomized open-label study in 66 patients with metastatic renal cell carcinoma found objective response rates of 25% with simluk…
Adding bevacizumab nearly tripled the time before kidney cancer grew back compared to a two-drug mix in this early study.